Desvenlafaxine in the treatment of major depressive disorder

Maria Teresa C Lourenco1, Sidney H Kennedy1,21Department of Psychiatry, University Health Network, Toronto; 2Department of Psychiatry, University of Toronto, Toronto, CanadaAbstract: Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the select...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Teresa C Lourenco1, Sidney H Kennedy1,2
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8043b3d2f9754bdfbcbd3a07a856cddc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8043b3d2f9754bdfbcbd3a07a856cddc
record_format	dspace
spelling	oai:doaj.org-article:8043b3d2f9754bdfbcbd3a07a856cddc2021-12-02T06:40:00ZDesvenlafaxine in the treatment of major depressive disorder1176-63281178-2021https://doaj.org/article/8043b3d2f9754bdfbcbd3a07a856cddc2009-02-01T00:00:00Zhttp://www.dovepress.com/desvenlafaxine-in-the-treatment-of-major-depressive-disorder-a2877https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Maria Teresa C Lourenco1, Sidney H Kennedy1,21Department of Psychiatry, University Health Network, Toronto; 2Department of Psychiatry, University of Toronto, Toronto, CanadaAbstract: Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) antidepressants has improved the treatment of MDD. Desvenlafaxine succinate (DVS) is the succinate salt of the isolated major active metabolite of venlafaxine, O-desmethylvenlafaxine: it is the third SNRI to become available in the United States, and was approved in 2008 by the US Food and Drug Administration (FDA) for the treatment of MDD. Early investigations showed therapeutic efficacy for doses between 50 and 400 mg/day; however in doses above 100 mg/day there were incremental increases in side effects. Nausea was the most frequent adverse effect. Hence the recommended dosing for DVS is in the 50 to 100 mg range. Desvenlafaxine is excreted in urine, it is minimally metabolized via the CYP450 pathway, and is a weak inhibitor of CYP2D6. A reduced risk for pharmacokinetic drug interactions is a potential advantage over other SNRI. Further head-to-head trials involving comparisons of DVS in the 50 to 100 mg dose range with currently available SSRI and SNRI antidepressants are required. Evidence for relapse prevention is available in the 200 to 400 mg dose range, but this needs to be demonstrated in the 50 to 100 mg dose range, as well as health economic measures and quality of life evaluations.Keywords: desvenlafaxine, O-desmethylvenlafaxine, Pristiq&reg;, SNRIs, MDD Maria Teresa C Lourenco1Sidney H Kennedy1,2Dove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 127-136 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Maria Teresa C Lourenco1 Sidney H Kennedy1,2 Desvenlafaxine in the treatment of major depressive disorder
description	Maria Teresa C Lourenco1, Sidney H Kennedy1,21Department of Psychiatry, University Health Network, Toronto; 2Department of Psychiatry, University of Toronto, Toronto, CanadaAbstract: Major depressive disorder (MDD) is among the most incapacitating conditions in the world. The emergence of the selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) antidepressants has improved the treatment of MDD. Desvenlafaxine succinate (DVS) is the succinate salt of the isolated major active metabolite of venlafaxine, O-desmethylvenlafaxine: it is the third SNRI to become available in the United States, and was approved in 2008 by the US Food and Drug Administration (FDA) for the treatment of MDD. Early investigations showed therapeutic efficacy for doses between 50 and 400 mg/day; however in doses above 100 mg/day there were incremental increases in side effects. Nausea was the most frequent adverse effect. Hence the recommended dosing for DVS is in the 50 to 100 mg range. Desvenlafaxine is excreted in urine, it is minimally metabolized via the CYP450 pathway, and is a weak inhibitor of CYP2D6. A reduced risk for pharmacokinetic drug interactions is a potential advantage over other SNRI. Further head-to-head trials involving comparisons of DVS in the 50 to 100 mg dose range with currently available SSRI and SNRI antidepressants are required. Evidence for relapse prevention is available in the 200 to 400 mg dose range, but this needs to be demonstrated in the 50 to 100 mg dose range, as well as health economic measures and quality of life evaluations.Keywords: desvenlafaxine, O-desmethylvenlafaxine, Pristiq&reg;, SNRIs, MDD
format	article
author	Maria Teresa C Lourenco1 Sidney H Kennedy1,2
author_facet	Maria Teresa C Lourenco1 Sidney H Kennedy1,2
author_sort	Maria Teresa C Lourenco1
title	Desvenlafaxine in the treatment of major depressive disorder
title_short	Desvenlafaxine in the treatment of major depressive disorder
title_full	Desvenlafaxine in the treatment of major depressive disorder
title_fullStr	Desvenlafaxine in the treatment of major depressive disorder
title_full_unstemmed	Desvenlafaxine in the treatment of major depressive disorder
title_sort	desvenlafaxine in the treatment of major depressive disorder
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/8043b3d2f9754bdfbcbd3a07a856cddc
work_keys_str_mv	AT mariateresaclourenco1 desvenlafaxineinthetreatmentofmajordepressivedisorder AT sidneyhkennedy12 desvenlafaxineinthetreatmentofmajordepressivedisorder
_version_	1718399820525207552

Desvenlafaxine in the treatment of major depressive disorder

Ejemplares similares